Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis

English version České info

Background:
It is now a decade since the World Trade Organization (WTO) adopted the “Declaration on the TRIPS Agreement and Public Health” at its 4th Ministerial Conference in Doha. Many anticipated that these actions would lead nations to claim compulsory licenses (CLs) for pharmaceutical products with greater regularity. A CL is the use of a patented innovation that has been licensed by a state without the permission of the patent title holder. Skeptics doubted that many CLs would occur, given political pressure against CL activity and continued health system weakness in poor countries. The subsequent decade has seen little systematic assessment of the Doha Declaration's impact.

Methods and Findings:
We assembled a database of all episodes in which a CL was publically entertained or announced by a WTO member state since 1995. Broad searches of CL activity were conducted using media, academic, and legal databases, yielding 34 potential CL episodes in 26 countries. Country- and product-specific searches were used to verify government participation, resulting in a final database of 24 verified CLs in 17 nations. We coded CL episodes in terms of outcome, national income, and disease group over three distinct periods of CL activity. Most CL episodes occurred between 2003 and 2005, involved drugs for HIV/AIDS, and occurred in upper-middle-income countries (UMICs). Aside from HIV/AIDS, few CL episodes involved communicable disease, and none occurred in least-developed or low-income countries.

Conclusions:
Given skepticism about the Doha Declaration's likely impact, we note the relatively high occurrence of CLs, yet CL activity has diminished markedly since 2006. While UMICs have high CL activity and strong incentives to use CLs compared to other countries, we note considerable countervailing pressures against CL use even in UMICs. We conclude that there is a low probability of continued CL activity. We highlight the need for further systematic evaluation of global health governance actions.

: Please see later in the article for the Editors' Summary

Vyšlo v časopise: Trends in Compulsory Licensing of Pharmaceuticals Since the Doha Declaration: A Database Analysis. PLoS Med 9(1): e32767. doi:10.1371/journal.pmed.1001154
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001154

Souhrn

Zdroje

1. World Trade Organization 2001 November 20 Declaration on the TRIPS agreement and public health. Available: http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm. Accessed 3 September 2011

2. World Trade Organization 2003 September 1 Implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health. Available: http://www.wto.org/english/tratop_e/trips_e/implem_para6_e.htm. Accessed 3 September 2011

3. BantaD 2001 Public health triumphs at WTO Conference. JAMA 286 2655 2656

4. KanthR 2003 September 2 WTO drug deal to spark competition Business Times Singapore

5. AttaranA 2004 How do patents and economic policies affect access to essential medicines in developing countries? Health Aff 23 155 166

6. World Trade Organization 2011 Intellectual property: protection and enforcement. Available: http://www.wto.org/english/thewto_e/whatis_e/tif_e/agrm7_e.htm. Accessed 3 September 2011

7. CorreaC 2003 Managing the provision of knowledge: the design of intellectual property laws. KaulIConceicaoPLe GoulvenKMendozaRU Providing global public goods: managing globalization Oxford Oxford University Press 410 430

8. World Health Organization 2008 February Briefing note: access to medicines—country experiences in using TRIPS safeguards. Available: http://www.searo.who.int/LinkFiles/IPT_Briefing_note_4_country_experiences.pdf. Accessed 3 September 2011

9. World Trade Organization 2006 September TRIPS and pharmaceutical patents: obligations and exceptions. Available: http://www.wto.org/english/tratop_e/trips_e/factsheet_pharm02_e.htm#art31. Accessed 3 September 2011

10. World Trade Organization 2006 September 21 Pharmaceutical patents and the TRIPS Agreement. Available: http://www.wto.org/english/tratop_e/trips_e/pharma_ato186_e.htm. Accessed 3 September 2011

11. World Trade Organization 2011 Frequently asked questions about TRIPS. Available: http://www.wto.org/english/tratop_e/trips_e/tripfq_e.htm#Transition. Accessed 3 September 2011

12. World Trade Organization 2011 Developing countries' transition periods. Available: http://www.wto.org/english/tratop_e/trips_e/factsheet_pharm04_e.htm. Accessed 3 September 2011

13. MurthyD 2002 The future of compulsory licensing: deciphering the Doha Declaration on the TRIPS Agreement and public health. Am Univ Int Law Rev 17 1299 1346

14. HarmonAPearR 2001 October 19 Canada overrides patent for Cipro to treat anthrax. New York Times. Available: http://www.nytimes.com/2001/10/19/business/19CANA.html. Accessed 3 April 2011

15. CurtiAM 2001 The WTO dispute settlement understanding: an unlikely weapon in the fight against AIDS. Am J Law Med 27 469 485

16. CorreaC 2002 June Implications of the Doha Declaration on the TRIPS Agreement and Public Health. Health economics and drugs series, no. 012 Geneva World Health Organization Available: http://apps.who.int/medicinedocs/en/d/Js2301e/. Accessed 3 September 2011

17. World Trade Organization 2001 November 9–13 Press pack—4th Ministerial Conference Doha. Available: http://www.wto.org/english/thewto_e/minist_e/min01_e/brief_e/doha_presspack_e.pdf. Accessed 3 September 2011

18. World Trade Organization 2005 December 8 Amendment of the TRIPS Agreement. Available: http://www.wto.org/english/tratop_e/trips_e/wtl641_e.htm. Accessed 3 September 2011

19. World Trade Organization 2009 December 18 Amendment of the TRIPS Agreement—second extension of the period for the acceptance of members of the protocol amending the TRIPS Agreement. Available: http://www.wto.org/english/tratop_e/trips_e/wt-l-785_e.pdf. Accessed 3 September 2011

20. World Trade Organization 2011 TRIPS and public health news archive. Available: http://www.wto.org/english/news_e/archive_e/trips_health_arc_e.htm. Accessed 3 September 2011

21. ReichMR 2000 March 17 The global drug gap. Science 287 1979 1981 Available: http://134.174.190.199/faculty/michael-reich/files/global_drug_gap.pdf. Accessed 3 September 2011

22. CohenJCGyansa-LutterodtMTorpeyKEsmailLCKurokawaG 2005 December 9 TRIPS, the Doha Declaration and increasing access to medicines: policy options for Ghana. Global Health 1 17 Available: http://www.biomedcentral.com/content/pdf/1744-8603-1-17.pdf. Accessed 3 September 2011

23. SmithRDCorreaCOhC 2009 Trade, TRIPS, and pharmaceuticals. Lancet 373 684 691

24. World Health Organization 2011 WHO model lists of essential medicines. Available: http://www.who.int/medicines/publications/essentialmedicines/en/. Accessed 4 December 2011

25. OliveiraMABermudezJAZChavesGCVelásquezG 2004 Has the implementation of the TRIPS agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health? Bull World Health Organ 82 815 821

26. ChavesGCOliveiraMA 2007 A proposal for measuring the degree of public health-sensitivity of patent legislation in the context of the WTO TRIPS Agreement. Bull World Health Organ 85 49 56

27. Van GelderAStevensP 2010 November The compulsory license red herring London International Policy Network Available: http://www.minimalgovernment.net/media/compulsory-201011.pdf. Accessed 11 June 2011

28. Consumer Project on Technology 2010 Health care and intellectual property: compulsory licensing. Available: http://www.cptech.org/ip/health/cl/. Accessed 3 April 2011

29. BucknellD 2007 October 22 The global IP scorecard for pharma and biotech compulsory licenses. Mondaq Business Briefing. Available: http://www.mondaq.com/australia/article.asp?articleid=53442. Accessed 3 April 2011

30. BeallR 2010 Trends in international compulsory licensing for pharmaceuticals since the institution of the Trade Related Aspects of Intellectual Property Rights (TRIPS) Agreement [Master's thesis] Denver Josef Korbel School of International Studies, Global Health Affairs, University of Denver

31. LexisNexis 2011 About us. Available: http://www.lexisnexis.com/about-us/. Accessed 3 September 2011

32. World Trade Organization 2010 TRIPS and public health ‘paragraph 6’ system: notifications by importing WTO members. Available: http://www.wto.org/english/tratop_e/trips_e/public_health_notif_import_e.htm. Accessed 3 September 2011

33. HestermeyerHP 2007 December Canadian-made drugs for Rwanda: the first application of the WTO waiver on patents and medicines. Am Soc Int Law Insights 10 Available: http://www.asil.org/insights/2007/12/insights071210.html. Accessed 3 September 2011

34. SekalalaSR 2010 February Third world access to essential medicines and the WTO General Council Decision 2003. King's Law J 21 172 192

35. AyodeleT 2008 April 28 Africa's failing infrastructure renders compulsory licensing pointless. The New Times (Kigali, Rwanda). Available: http://www.newtimes.co.rw/index.php?issue=13515&article=5935. Accessed 29 November 2011

36. DuggerCW 2007 May 9 Clinton Foundation announces a bargain on generic AIDS drugs. New York Times. Available: http://www.nytimes.com/2007/05/09/world/09aidsdrugs.html. Accessed 3 September 2011

37. WaningBDiedrichsenEMoonS 2010 September 14 A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries. J Int AIDS Soc 13 35 Available: http://www.jiasociety.org/content/13/1/35. Accessed 3 September 2011

38. SavoieB 2007 Thailand's test: compulsory licensing in an era of the epidemiological transition. Va J Int Law 48 211 248

39. Commission on Intellectual Property Rights, Innovation and Public Health 2006 April Public health: innovation and intellectual property rights Geneva World Health Organization Available: http://www.who.int/intellectualproperty/documents/thereport/CIPIH23032006.pdf. Accessed 3 April 2011